{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:26:44Z","timestamp":1761128804657},"publisher-location":"Chichester, UK","reference-count":48,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002009.pub3","type":"reference-entry","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T13:49:30Z","timestamp":1263822570000},"source":"Crossref","is-referenced-by-count":10,"title":["Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Alan R","family":"Smyth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayesh","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"10.1002\/14651858.CD002009.pub3-BIB1|cit1","series-title":"13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden","first-page":"166","article-title":"Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract]","author":"Riethmueller","year":"2000"},{"key":"10.1002\/14651858.CD002009.pub3-BIB2|cit2","series-title":"Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria","first-page":"P192","article-title":"Optimized intravenous antibiotic treatment with ceftazidime (thrice-daily vs. continuous) and tobramycin (thrice vs. once-daily) in CF patients [abstract]","author":"Riethmueller","year":"2001"},{"issue":"Suppl 24","key":"10.1002\/14651858.CD002009.pub3-BIB3|cit3","first-page":"289","article-title":"Acute-phase nephrotoxicity of tobramycin in CF patients: a prospective randomized trial of once- versus thrice-daily dosing","volume":"34","author":"Schroeter","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002009.pub3-BIB4|cit4","series-title":"Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria","first-page":"P190","article-title":"A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract]","author":"Schroeter","year":"2001"},{"issue":"7","key":"10.1002\/14651858.CD002009.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.00995-05","article-title":"Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients","volume":"50","author":"Mulheran","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002009.pub3-BIB6|cit6","first-page":"iii84","article-title":"Once daily tobramycin achieves cidal levels against Pseudomonas aeruginosa in patients with cystic fibrosis [abstract]","volume":"56","author":"Smyth","year":"2001","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002009.pub3-BIB8|cit7","series-title":"Pediatric Pulmonology","first-page":"292","article-title":"A randomised controlled trial of once vs three times daily tobramycin for pulmonary exacerbations of cystic fibrosis [abstract]","author":"Smyth","year":"2003"},{"issue":"9459","key":"10.1002\/14651858.CD002009.pub3-BIB7|cit8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once vs. three times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002009.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(07)60054-X","article-title":"Population pharmacokinetics (PK) of tobramycin administered thrice daily (TD) and once daily (OD) in children and adults with CF [abstract]","volume":"6","author":"Touw","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD002009.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","article-title":"Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis","volume":"6","author":"Touw","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002009.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(05)17919-7","article-title":"Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs [comment]","volume":"365","author":"VandenBussche","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002009.pub3-BIB12|cit12","first-page":"449","article-title":"Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in three doses in cystic fibrosis","volume":"46","author":"Canis","year":"1998","journal-title":"Pathologie-biologie"},{"issue":"6","key":"10.1002\/14651858.CD002009.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/adc.78.6.536","article-title":"Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis","volume":"78","author":"Vic","year":"1998","journal-title":"Archives of Disease in Childhood"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD002009.pub3-BIB14|cit14","first-page":"293","article-title":"Efficacy, tolerance and pharmokinetics of once-daily (OD) versus thrice-daily (TD) Tobramycine (TBM) for Pseudomonas aeruginosa (PA) pulmonary exacerbations [abstract]","volume":"22","author":"Vic","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD002009.pub3-BIB15|cit15","first-page":"262","article-title":"Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]","volume":"28","author":"Watson","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD002009.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1183\/09031936.02.00221602","article-title":"Once-daily tobramycin in the treatment of adult patients with cystic fibrosis","volume":"19","author":"Whitehead","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD002009.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0300-2977(99)90103-1","article-title":"Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]","volume":"54","author":"Whitehead","year":"1999","journal-title":"The Netherlands Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002009.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/dkf168","article-title":"Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis","volume":"50","author":"Aminimanizani","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD002009.pub3-BIB19|cit19","first-page":"284","article-title":"Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients [abstract]","volume":"30","author":"Tsang","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD002009.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/jac\/dkl328","article-title":"Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?","volume":"58","author":"Burkhardt","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"S29","key":"10.1002\/14651858.CD002009.pub3-BIB21|cit21","first-page":"326","article-title":"Pharmacokinetics and safety of once-daily tobramycin in children with cystic fibrosis","volume":"41","author":"Hamner","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD002009.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1025191","article-title":"Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration","volume":"205","author":"Heininger","year":"1993","journal-title":"Klinische Padiatrie"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD002009.pub3-BIB23|cit23","first-page":"162s","article-title":"Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients [abstract]","volume":"10","author":"Master","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002009.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ppul.1060","article-title":"Efficacy of Once-daily Tobramycin Monotherapy for Acute Pulmonary Exacerbations of Cystic Fibrosis: A Preliminary Study","volume":"31","author":"Master","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002009.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1569-1993(07)60126-X","article-title":"A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients [abstract]","volume":"6","author":"Postnikov","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002009.pub3-BIB26|cit26","series-title":"20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia","article-title":"Safety of once daily therapy with high-dose tobramycin [abstract]","author":"Powell","year":"1979"},{"issue":"5","key":"10.1002\/14651858.CD002009.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/infdis\/147.5.918","article-title":"Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin","volume":"147","author":"Powell","year":"1983","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD002009.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00006454-199105000-00007","article-title":"Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"10","author":"Winnie","year":"1991","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD002009.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/thx.51.4.369","article-title":"Minimisation of aminoglycoside toxicity in patients with cystic fibrosis","volume":"51","author":"Wood","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002009.pub3-BIB30|cit30","unstructured":"Tureen J Once Daily Intravenous Aminoglycoside Treatment Study U.S. Cystic Fibrosis Foundation"},{"issue":"1","key":"10.1002\/14651858.CD002009.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ppul.20138","article-title":"Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use","volume":"39","author":"Al Aloul","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"7027","key":"10.1002\/14651858.CD002009.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bmj.312.7027.338","article-title":"Single or multiple daily dosing of aminoglycosides: a meta-analysis","volume":"312","author":"Barza","year":"1996","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD002009.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/thx.2006.067595","article-title":"Survey of acute renal failure in patients with cystic fibrosis in the UK","volume":"62","author":"Bertenshaw","year":"2007","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002009.pub3-BIB34|cit34","unstructured":"UK Cystic Fibrosis Trust Antibiotic Group Antibiotic treatment for cystic fibrosis Report of the UK Cystic Fibrosis Trust Antibiotic Group 2009"},{"issue":"9028","key":"10.1002\/14651858.CD002009.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(96)05169-0","article-title":"Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002009.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/014107688908200303","article-title":"Intravenous antibiotics at home in children with cystic fibrosis","volume":"82","author":"David","year":"1986","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002009.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/ajrccm.154.5.8912731","article-title":"Cystic fibrosis","volume":"154","author":"Davis","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002009.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","article-title":"Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance","volume":"13","author":"Groot","year":"1987","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"10.1002\/14651858.CD002009.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD002009.pub3-BIB40|cit40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002007.pub2","article-title":"Single versus combination intravenous antibiotic therapy for people with cystic fibrosis","author":"Elphick","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD002009.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD002009.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002009.pub3-BIB43|cit43","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]","author":"Higgins","year":"2008"},{"issue":"7048","key":"10.1002\/14651858.CD002009.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence: the importance of rigorous methods","volume":"313","author":"Jones","year":"1996","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD002009.pub3-BIB45|cit45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thx.2007.088757","article-title":"Case-control study of acute renal failure in patients with cystic fibrosis in the UK","volume":"63","author":"Smyth","year":"2008","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD002009.pub3-BIB46|cit46","first-page":"865","article-title":"The post antibiotic effect","volume":"11","author":"Spivey","year":"1992","journal-title":"Clinical Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD002009.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ppul.10036","article-title":"Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centres","volume":"33","author":"Tan","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD002009.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1128\/AAC.39.11.2411","article-title":"Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by pseudomonas aeruginosa","volume":"39","author":"Weiss","year":"1995","journal-title":"Antimicrobial Agents and Chemotherapy"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD002009.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:08:12Z","timestamp":1628543292000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002009.pub3"}},"subtitle":[],"editor":[{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002009.pub3","relation":{},"subject":[],"published":{"date-parts":[[2010,1,20]]}}}